CL2024003262A1 - Inhibidores de parp1 tricíclicos y usos de estos - Google Patents
Inhibidores de parp1 tricíclicos y usos de estosInfo
- Publication number
- CL2024003262A1 CL2024003262A1 CL2024003262A CL2024003262A CL2024003262A1 CL 2024003262 A1 CL2024003262 A1 CL 2024003262A1 CL 2024003262 A CL2024003262 A CL 2024003262A CL 2024003262 A CL2024003262 A CL 2024003262A CL 2024003262 A1 CL2024003262 A1 CL 2024003262A1
- Authority
- CL
- Chile
- Prior art keywords
- tricyclic
- parp1 inhibitors
- inhibitors
- parp1
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263336078P | 2022-04-28 | 2022-04-28 | |
| US202263381482P | 2022-10-28 | 2022-10-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2024003262A1 true CL2024003262A1 (es) | 2025-03-14 |
Family
ID=88420972
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024003262A CL2024003262A1 (es) | 2022-04-28 | 2024-10-25 | Inhibidores de parp1 tricíclicos y usos de estos |
| CL2025002554A CL2025002554A1 (es) | 2022-04-28 | 2025-08-25 | Compuestos tricíclicos inhibidores de parp1 y uso para tratar cáncer. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2025002554A CL2025002554A1 (es) | 2022-04-28 | 2025-08-25 | Compuestos tricíclicos inhibidores de parp1 y uso para tratar cáncer. |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US11795173B1 (da) |
| EP (3) | EP4355749B1 (da) |
| JP (2) | JP7728989B2 (da) |
| KR (2) | KR102903399B1 (da) |
| CN (1) | CN119173516A (da) |
| AU (2) | AU2023259236B2 (da) |
| CA (1) | CA3250945A1 (da) |
| CL (2) | CL2024003262A1 (da) |
| CO (1) | CO2024014603A2 (da) |
| CR (1) | CR20240461A (da) |
| DK (2) | DK4497438T3 (da) |
| DO (1) | DOP2024000218A (da) |
| ES (2) | ES3050217T3 (da) |
| FI (2) | FI4497438T3 (da) |
| HR (2) | HRP20251173T1 (da) |
| HU (1) | HUE072274T2 (da) |
| IL (1) | IL316278A (da) |
| LT (2) | LT4497438T (da) |
| MX (2) | MX2024013195A (da) |
| NZ (1) | NZ815323A (da) |
| PL (2) | PL4355749T3 (da) |
| PT (2) | PT4355749T (da) |
| SI (2) | SI4355749T1 (da) |
| TW (2) | TWI891000B (da) |
| WO (1) | WO2023212219A1 (da) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117980307A (zh) * | 2021-08-27 | 2024-05-03 | 上海瑛派药业有限公司 | 取代的三环类化合物作为parp抑制剂及其应用 |
| AU2023209820B2 (en) | 2022-01-21 | 2024-10-10 | Xinthera, Inc. | Parp1 inhibitors and uses thereof |
| IL315586A (en) * | 2022-03-11 | 2024-11-01 | Impact Therapeutics Shanghai Inc | Substituted tricyclic compounds as parp inhibitors and the use thereof |
| KR20240161147A (ko) | 2022-03-14 | 2024-11-12 | 슬랩 파마슈티컬스 엘엘씨 | 다중 사이클릭 화합물 |
| CA3250945A1 (en) | 2022-04-28 | 2023-11-02 | Xinthera, Inc. | TRICYCLIC PARP1 INHIBITORS AND THEIR USES |
| CN117263943A (zh) * | 2022-09-09 | 2023-12-22 | 轩竹生物科技股份有限公司 | 聚（adp核糖）聚合酶选择性抑制剂 |
| JP2025538192A (ja) * | 2022-11-10 | 2025-11-26 | 上海海和薬物研究開発股▲ふん▼有限公司 | 縮合三環式ｐａｒｐ１阻害剤、その調製方法、および使用 |
| TW202525808A (zh) * | 2023-09-13 | 2025-07-01 | 大陸商上海瑛派藥業有限公司 | 用作ｐａｒｐ１抑制劑的化合物、其用途及包含其之組合物 |
| AU2024359243A1 (en) * | 2023-10-09 | 2026-04-23 | Incyte Corporation | Processes for preparing kras inhibitors |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPS137402A0 (en) | 2002-03-26 | 2002-05-09 | Fujisawa Pharmaceutical Co., Ltd. | Novel tricyclic compounds |
| PL2215075T3 (pl) | 2007-10-26 | 2014-04-30 | Janssen Pharmaceutica Nv | Pochodne chinolinonu jako inhibitory PARP |
| KR20100102646A (ko) | 2007-12-11 | 2010-09-24 | 가부시키가이샤 사이토파스파인더 | 카르복스아미드 화합물 및 케모카인 수용체 길항제로서의 이의 용도 |
| MA33053B1 (fr) | 2009-01-23 | 2012-02-01 | Tadeka Pharmaceutical Company Ltd | Inhibiteurs de la poly(adp-ribose) polymerase (parp) |
| JP5715625B2 (ja) | 2009-07-30 | 2015-05-07 | 武田薬品工業株式会社 | ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤 |
| SG179163A1 (en) | 2009-09-16 | 2012-05-30 | Cylene Pharmaceuticals Inc | Novel tricyclic protein kinase modulators |
| CN104768948B (zh) | 2012-10-26 | 2018-11-27 | 内尔维阿诺医学科学有限公司 | 作为选择性parp-1抑制剂的4-甲酰氨基-异二氢吲哚酮衍生物 |
| CN104370898A (zh) | 2013-08-14 | 2015-02-25 | 黄传满 | 咪唑并[1,2-a]吡啶类化合物及其制备方法和用途 |
| JP2017508798A (ja) | 2014-03-07 | 2017-03-30 | ザ ジョンズ ホプキンス ユニバーシティ | ヒストンリジン特異的デメチラーゼ（ｌｓｄ１）およびヒストンデアセチラーゼ（ｈｄａｃ）の阻害剤 |
| CN105753814A (zh) | 2015-01-01 | 2016-07-13 | 成都贝斯凯瑞生物科技有限公司 | 取代氮杂环衍生物及其应用 |
| ES2870203T3 (es) | 2015-06-09 | 2021-10-26 | Onconic Therapeutics Inc | Compuesto derivado tricíclico, método para prepararlo y composición farmacéutica que comprende el mismo |
| MX2018001871A (es) | 2015-08-17 | 2018-05-28 | Lupin Ltd | Derivados de heteroarilo como inhibidores de parp. |
| ES2905676T3 (es) | 2017-05-22 | 2022-04-11 | Amgen Inc | Inhibidores de KRAS G12C y métodos para su uso |
| IL283127B1 (en) | 2018-11-14 | 2026-02-01 | Smilebiotek Zhuhai Ltd | Animal-based models, scanning methods, and methods of treating intraocular diseases or disorders |
| HUE071067T2 (hu) | 2019-07-19 | 2025-07-28 | Astrazeneca Ab | PARP1 inhibitorok |
| KR102293986B1 (ko) | 2019-10-30 | 2021-08-26 | 충남대학교산학협력단 | 이소퀴놀리논 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 폴리(adp-리보스)폴리머라제-1(parp-1) 관련 질환의 예방 또는 치료용 약학적 조성물 |
| US11795158B2 (en) * | 2020-06-25 | 2023-10-24 | Astrazeneca Ab | Chemical compounds |
| CA3216373A1 (en) | 2021-04-19 | 2022-10-27 | Lynnie TRZOSS | Parp1 inhibitors and uses thereof |
| AU2022261011A1 (en) | 2021-04-22 | 2023-11-16 | Wigen Biomedicine Technology (shanghai) Co., Ltd. | Parp inhibitor containing piperazine structure, preparation method therefor and pharmaceutical use thereof |
| CN115702156A (zh) | 2021-04-23 | 2023-02-14 | 南京明德新药研发有限公司 | 吡啶酰胺类化合物 |
| WO2022223025A1 (zh) | 2021-04-23 | 2022-10-27 | 上海翰森生物医药科技有限公司 | 杂环类衍生物抑制剂、其制备方法和应用 |
| WO2022222966A1 (zh) | 2021-04-23 | 2022-10-27 | 成都百裕制药股份有限公司 | 一种选择性parp1抑制剂及其应用 |
| CN115232121B (zh) | 2021-04-23 | 2023-08-29 | 成都百裕制药股份有限公司 | 吡啶衍生物及其在医药上的应用 |
| WO2022228387A1 (en) | 2021-04-26 | 2022-11-03 | Fochon Biosciences, Ltd. | Compounds as parp inhibitors |
| US20240287094A1 (en) | 2021-05-24 | 2024-08-29 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Nitrogen-containing heterocyclic compound, preparation method therefor, and application thereof in medicines |
| CN115403595A (zh) | 2021-05-27 | 2022-11-29 | 江苏恒瑞医药股份有限公司 | 含氮杂环类化合物、其制备方法及其在医药上的应用 |
| IL309388A (en) | 2021-06-16 | 2024-02-01 | Repare Therapeutics Inc | Combining ATR inhibitors and PARP inhibitors for cancer treatment |
| CN117980307A (zh) * | 2021-08-27 | 2024-05-03 | 上海瑛派药业有限公司 | 取代的三环类化合物作为parp抑制剂及其应用 |
| WO2023036285A1 (zh) | 2021-09-09 | 2023-03-16 | 南京奥利墨斯医药科技有限公司 | 一种杂芳环类化合物及其应用 |
| WO2023046034A1 (zh) | 2021-09-22 | 2023-03-30 | 明慧医药（杭州）有限公司 | 一种含氮杂环化合物、其制备方法、其中间体及其应用 |
| WO2023046149A1 (zh) | 2021-09-26 | 2023-03-30 | 张文燕 | 喹喔啉类化合物及其医药用途 |
| WO2023046158A1 (zh) | 2021-09-26 | 2023-03-30 | 张文燕 | 氮杂喹啉酮类化合物及其医药用途 |
| US20240400586A1 (en) | 2021-09-30 | 2024-12-05 | Haisco Pharmaceutical Group Co., Ltd. | Heteroaryl derivative parp inhibitor and use thereof |
| CN118043322A (zh) | 2021-09-30 | 2024-05-14 | 西藏海思科制药有限公司 | 含氮杂环衍生物parp抑制剂及其用途 |
| EP4410791A4 (en) | 2021-09-30 | 2025-10-22 | Xizang Haisco Pharmaceutical Co Ltd | BICYCLIC DERIVATIVE PARP INHIBITOR AND ITS USE |
| CR20240144A (es) | 2021-10-01 | 2024-05-24 | Xinthera Inc | Inhibidores de parp1 de azetidina y pirrolidina y usos de estos |
| WO2023061406A1 (zh) | 2021-10-12 | 2023-04-20 | 微境生物医药科技(上海)有限公司 | 含三并环结构的parp抑制剂、及其制备方法和医药用途 |
| JP7762306B2 (ja) | 2021-11-19 | 2025-10-29 | 康百達（四川）生物医薬科技有限公司 | 選択的ｐａｒｐ１阻害剤およびその用途 |
| CN116143776A (zh) | 2021-11-22 | 2023-05-23 | 南京圣和药业股份有限公司 | Parp1抑制剂及其应用 |
| JP7804371B2 (ja) | 2021-12-17 | 2026-01-22 | キーセラ（スーチョウ）バイオ－ファーマスーティカルズ カンパニー，リミテッド | Ｐａｒｐ阻害剤、それを含む医薬組成物及びそれらの使用 |
| WO2023133413A1 (en) | 2022-01-07 | 2023-07-13 | Slap Pharmaceuticals Llc | Multicyclic compounds |
| WO2023134647A1 (zh) | 2022-01-13 | 2023-07-20 | 优领医药科技(香港)有限公司 | 含哌嗪并环类衍生物、其药学上可接受的盐及其制备方法和应用 |
| CN118434725B (zh) | 2022-01-20 | 2026-01-02 | 微境生物医药科技(上海)有限公司 | 吡啶酰胺类parp抑制剂、及其制备方法和医药用途 |
| AU2023209820B2 (en) | 2022-01-21 | 2024-10-10 | Xinthera, Inc. | Parp1 inhibitors and uses thereof |
| CN116535401A (zh) | 2022-01-25 | 2023-08-04 | 南京圣和药业股份有限公司 | 新的parp1抑制剂及其应用 |
| WO2023143236A1 (zh) | 2022-01-26 | 2023-08-03 | 中国药科大学 | 2h-吲唑-7-甲酰胺类化合物、制备方法、药物组合物和应用 |
| WO2023147009A1 (en) | 2022-01-27 | 2023-08-03 | The Johns Hopkins University | Clinical-grade therapeutic progenitors generated from tankyrase/parp-inhibited pluripotent stem cell banks |
| EP4469449A4 (en) | 2022-01-27 | 2026-02-25 | Xinthera Inc | PARP1 INHIBITORS AND THEIR USES |
| KR20230116457A (ko) | 2022-01-28 | 2023-08-04 | 경북대학교 산학협력단 | 작약 추출물을 포함하는 만성폐쇄성폐질환 예방 또는 치료용 약학적 조성물 |
| EP4469046A1 (en) | 2022-01-28 | 2024-12-04 | Oulun Yliopisto | Compounds for use in the treatment of cancer and inflammatory conditions |
| CA3249318A1 (en) | 2022-01-28 | 2023-08-03 | Xinthera, Inc. | PARP1 INHIBITORS AND THEIR USES |
| IL314895A (en) | 2022-02-16 | 2024-10-01 | Duke Street Bio Ltd | Pharmaceutical compound |
| IL315586A (en) | 2022-03-11 | 2024-11-01 | Impact Therapeutics Shanghai Inc | Substituted tricyclic compounds as parp inhibitors and the use thereof |
| WO2023207284A1 (en) | 2022-04-28 | 2023-11-02 | Ningbo Newbay Technology Development Co., Ltd | Piperazine derivatives as parp1 inhibitiors |
| EP4514795A4 (en) | 2022-04-28 | 2025-12-31 | Ningbo Newbay Tech Development Co Ltd | COMPOUNDS USED AS PARP1 INHIBITORS |
| CA3250945A1 (en) | 2022-04-28 | 2023-11-02 | Xinthera, Inc. | TRICYCLIC PARP1 INHIBITORS AND THEIR USES |
| JP7835895B2 (ja) | 2022-05-07 | 2026-03-25 | サイブランチ セラピューティクス カンパニー リミテッド | Ｐａｒｐ１を選択的に阻害するフルオロキノキサリノン誘導体 |
| AU2023275808A1 (en) | 2022-05-25 | 2024-12-12 | Xizang Haisco Pharmaceutical Co., Ltd. | Bicyclic derivative parp inhibitor and use thereof |
| EP4534533A4 (en) | 2022-06-02 | 2026-04-29 | Chengdu Easton Biopharmaceuticals Co Ltd | AZAQUINOLINONE DERIVATIVE, ITS PREPARATION PROCESS AND ITS USE |
| CN117447449A (zh) | 2022-07-13 | 2024-01-26 | 南京圣和药业股份有限公司 | Parp1抑制剂及其应用 |
| CN115232129B (zh) | 2022-08-18 | 2023-12-01 | 上海闻耐医药科技有限公司 | 一种parp1选择性抑制剂及其制备方法和用途 |
| WO2024041643A1 (zh) | 2022-08-25 | 2024-02-29 | 江苏恒瑞医药股份有限公司 | 稠合三环类化合物、其制备方法及其在医药上的应用 |
| US20240132449A1 (en) | 2022-08-30 | 2024-04-25 | 1Cbio, Inc. | Heterocyclic compounds and methods of use thereof |
| WO2024046420A1 (zh) | 2022-08-31 | 2024-03-07 | 江苏恒瑞医药股份有限公司 | 稠合二环类化合物、其制备方法及其在医药上的应用 |
| CN117658983A (zh) | 2022-09-01 | 2024-03-08 | 浙江文达医药科技有限公司 | 选择性parp1抑制剂 |
| WO2024067691A1 (zh) | 2022-09-30 | 2024-04-04 | 中国医药研究开发中心有限公司 | 含氮杂环类化合物及其医药用途 |
| TW202415658A (zh) | 2022-09-30 | 2024-04-16 | 大陸商中國醫藥研究開發中心有限公司 | 含氮雜環類化合物及其醫藥用途 |
| US20240174669A1 (en) | 2022-10-06 | 2024-05-30 | Xinthera, Inc. | Crystalline forms of a parp1 inhibitor |
| CN117946074A (zh) | 2022-10-20 | 2024-04-30 | 上海海和药物研究开发股份有限公司 | 具有parp1抑制活性的化合物及其用途 |
| CN120035592A (zh) | 2022-10-20 | 2025-05-23 | 成都赜灵生物医药科技有限公司 | 并杂环类氘代化合物及其用途 |
| CN117917407A (zh) | 2022-10-20 | 2024-04-23 | 成都赜灵生物医药科技有限公司 | 并杂环类化合物及其用途 |
| CN120019054A (zh) | 2022-10-20 | 2025-05-16 | 成都赜灵生物医药科技有限公司 | 取代四氢吡啶类化合物及其用途 |
| JP2025541981A (ja) | 2022-11-09 | 2025-12-24 | ラエクナ ファーマシューティカル ニンボー カンパニー リミテッド | 縮合多環式化合物及びｐａｒｐ１阻害剤としてのそれらの使用 |
| JP2025538192A (ja) | 2022-11-10 | 2025-11-26 | 上海海和薬物研究開発股▲ふん▼有限公司 | 縮合三環式ｐａｒｐ１阻害剤、その調製方法、および使用 |
| AU2023383898A1 (en) | 2022-11-23 | 2025-06-12 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutically acceptable salt of nitrogen-containing heterocyclic compound, crystal form thereof, and preparation method therefor |
| CN118084916A (zh) | 2022-11-25 | 2024-05-28 | 成都赜灵生物医药科技有限公司 | 三并杂环类化合物及其用途 |
| AU2024242411A1 (en) | 2023-03-24 | 2025-10-23 | Gilead Sciences, Inc. | Crystalline forms of an azetidine parp1 inhibitor |
| CN116987066B (zh) | 2023-06-20 | 2025-07-25 | 四川大学 | 一种嘧啶类化合物及其制备方法和应用 |
| CN117017962A (zh) | 2023-08-23 | 2023-11-10 | 复旦大学附属肿瘤医院 | 一种hdaci抑制剂在制备治疗卵巢癌药物中的用途 |
-
2023
- 2023-04-27 CA CA3250945A patent/CA3250945A1/en active Pending
- 2023-04-27 LT LTEP24217893.7T patent/LT4497438T/lt unknown
- 2023-04-27 SI SI202330037T patent/SI4355749T1/sl unknown
- 2023-04-27 SI SI202330046T patent/SI4497438T1/sl unknown
- 2023-04-27 JP JP2024563302A patent/JP7728989B2/ja active Active
- 2023-04-27 DK DK24217893.7T patent/DK4497438T3/da active
- 2023-04-27 KR KR1020247039178A patent/KR102903399B1/ko active Active
- 2023-04-27 ES ES24217893T patent/ES3050217T3/es active Active
- 2023-04-27 ES ES23797297T patent/ES3038967T3/es active Active
- 2023-04-27 FI FIEP24217893.7T patent/FI4497438T3/fi active
- 2023-04-27 DK DK23797297.1T patent/DK4355749T3/da active
- 2023-04-27 KR KR1020257042273A patent/KR20260004578A/ko active Pending
- 2023-04-27 NZ NZ815323A patent/NZ815323A/en unknown
- 2023-04-27 EP EP23797297.1A patent/EP4355749B1/en active Active
- 2023-04-27 EP EP25180004.1A patent/EP4620472A3/en active Pending
- 2023-04-27 PL PL23797297.1T patent/PL4355749T3/pl unknown
- 2023-04-27 PT PT237972971T patent/PT4355749T/pt unknown
- 2023-04-27 HU HUE23797297A patent/HUE072274T2/hu unknown
- 2023-04-27 TW TW112115680A patent/TWI891000B/zh active
- 2023-04-27 HR HRP20251173TT patent/HRP20251173T1/hr unknown
- 2023-04-27 EP EP24217893.7A patent/EP4497438B1/en active Active
- 2023-04-27 FI FIEP23797297.1T patent/FI4355749T3/fi active
- 2023-04-27 CN CN202380036872.0A patent/CN119173516A/zh active Pending
- 2023-04-27 TW TW114123039A patent/TW202540112A/zh unknown
- 2023-04-27 CR CR20240461A patent/CR20240461A/es unknown
- 2023-04-27 LT LTEPPCT/US2023/020235T patent/LT4355749T/lt unknown
- 2023-04-27 IL IL316278A patent/IL316278A/en unknown
- 2023-04-27 WO PCT/US2023/020235 patent/WO2023212219A1/en not_active Ceased
- 2023-04-27 AU AU2023259236A patent/AU2023259236B2/en active Active
- 2023-04-27 US US18/140,370 patent/US11795173B1/en active Active
- 2023-04-27 PT PT242178937T patent/PT4497438T/pt unknown
- 2023-04-27 PL PL24217893.7T patent/PL4497438T3/pl unknown
- 2023-04-27 HR HRP20250969TT patent/HRP20250969T1/hr unknown
- 2023-09-20 US US18/471,250 patent/US12006322B2/en active Active
-
2024
- 2024-05-02 US US18/653,538 patent/US12421241B2/en active Active
- 2024-10-25 MX MX2024013195A patent/MX2024013195A/es unknown
- 2024-10-25 CL CL2024003262A patent/CL2024003262A1/es unknown
- 2024-10-25 DO DO2024000218A patent/DOP2024000218A/es unknown
- 2024-10-25 MX MX2025008920A patent/MX2025008920A/es unknown
- 2024-10-25 CO CONC2024/0014603A patent/CO2024014603A2/es unknown
-
2025
- 2025-04-08 AU AU2025202495A patent/AU2025202495A1/en active Pending
- 2025-08-13 JP JP2025134784A patent/JP2025161856A/ja active Pending
- 2025-08-25 CL CL2025002554A patent/CL2025002554A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2024014603A2 (es) | Inhibidores de parp1 tricíclicos y usos de estos | |
| CO2024003949A2 (es) | Inhibidores de parp1 de azetidina y pirrolidina y usos de estos | |
| UY40021A (es) | Inhibidores lisina acetiltransferasa 6a (kat6a) y usos de los mismos | |
| CL2023002090A1 (es) | Inhibidores de kras tricíclicos fusionados | |
| DOP2023000285A (es) | Restos de administración terapéutica novedosos y usos de estos | |
| CO2025009612A2 (es) | Inhibidores de kif18a y usos de los mismos | |
| CO2023013150A2 (es) | Inhibidores de mk2 y usos de estos | |
| CL2024003450A1 (es) | Compuestos y usos de estos | |
| AR129980A1 (es) | Inhibidores de qpctl y qpct | |
| CO2022011258A2 (es) | Pirazolo-pirimidinas sustituidas y usos de las mismas | |
| CO2020013968A2 (es) | Derivados de pladeniolida como agentes dirigidos a empalmosoma para tratar el cáncer | |
| MX2018013519A (es) | Inhibidores del potenciador del homologo zeste 2. | |
| CL2024003870A1 (es) | Compuestos de degradación de wee1 y usos de los mismos | |
| MX2025008741A (es) | Inhibidores de la proteina 3 que contiene los dominios nod, lrr y pirina (nlrp3) | |
| AR132890A1 (es) | Aminas bicíclicas como inhibidores de cdk2 | |
| PY2435100A (es) | Inhibidores de egfr para el tratamiento de enfermedades | |
| AR126389A1 (es) | Compuestos tricíclicos como inhibidores de kras | |
| DOP2025000274A (es) | Inhibidores de egfr para el tratamiento de enfermedades | |
| AR131437A1 (es) | Compuestos inhibidores de pkmyt1 |